Examkin

Soru

Zorluk: ZorMonitoring and Treatment Evaluation

A 74-year-old man is evaluated in the cardiology clinic 3 days after being discharged from the hospital. He had been admitted for highly symptomatic, recurrent atrial fibrillation, and oral amiodarone was initiated for rhythm control prior to discharge. His medical history is significant for heart failure with reduced ejection fraction and a mechanical aortic valve replacement performed 4 years ago. His home medications include warfarin, digoxin, metoprolol succinate, and lisinopril. On the day of discharge, his international normalized ratio (INR) was 2.8 (target 2.5–3.5) and his serum digoxin level was 0.9 ng/mL (target 0.5–0.9 ng/mL). Today, the patient reports feeling well with no palpitations, visual disturbances, or bleeding. Vital signs are within normal limits. Which of the following is the most appropriate next step in the management of this patient's pharmacotherapy?

  1. Decrease the warfarin dose by 30% to 50% and decrease the digoxin dose by 50%Cevap
  2. B
    Decrease the digoxin dose by 50% and increase the warfarin dose by 25%
  3. C
    Decrease the warfarin dose by 30% to 50% and maintain the current digoxin dose
  4. D
    Discontinue warfarin and initiate a direct oral anticoagulant such as apixaban
  5. E
    Admit the patient to the hospital for continuous cardiac telemetry and intravenous heparin bridging

Cevap

Decrease the warfarin dose by 30% to 50% and decrease the digoxin dose by 50%
The correct answer accurately addresses the dual pharmacokinetic interactions caused by amiodarone. Amiodarone inhibits CYP2C9, which decreases the clearance of warfarin, requiring a preemptive 30% to 50% reduction in the weekly warfarin dose to prevent severe bleeding. Simultaneously, amiodarone inhibits P-glycoprotein, which decreases the clearance of digoxin, requiring a preemptive 50% reduction in the digoxin dose to avoid neurotoxicity and fatal arrhythmias. Because both existing drug levels were highly therapeutic on the day of discharge, failing to reduce either dose will predictably lead to toxic accumulation over the next several days.

Adım Adım Çözüm

1
Review the patient's current medication list against the newly initiated drug.
Amiodarone has been added to a regimen that already includes both warfarin and digoxin.
Identifying overlapping pharmacotherapies is essential for anticipating adverse drug reactions.
2
Analyze the specific pharmacokinetic mechanisms of the new medication.
Amiodarone is a potent inhibitor of both the cytochrome P450 2C9 (CYP2C9) enzyme and the P-glycoprotein (P-gp) efflux transporter.
Understanding the precise mechanism dictates the necessary dose adjustments for affected substrates.
3
Determine the required proactive dose adjustments for the affected home medications.
The warfarin dose must be reduced by 30% to 50% to account for CYP2C9 inhibition, and the digoxin dose must be reduced by 50% to account for P-gp inhibition.
Proactive dose reduction prevents supratherapeutic levels, which could lead to life-threatening bleeding and digoxin toxicity.

Anahtar Kavram

Proactive dose adjustments are mandatory when initiating amiodarone in patients taking warfarin (due to CYP2C9 inhibition) and digoxin (due to P-glycoprotein inhibition) to prevent severe toxicity.
Bu soruyu puanla

Konular

Monitoring and Treatment Evaluation

Bu konudan daha fazla soru